Gilead Prices $4 Billion of Senior Unsecured Notes

05-03-2014 Business Wire HealthComments (0)

BiotechnologyGilead SciencesPharmaceuticalUSA

Gilead Sciences (NASDAQ: GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $4 billion in an underwritten, registered public offering, consisting of three tranches: $500 million of 2.050% senior notes maturing in April 2019 $1,750 million of 3.700% senior notes maturing in April 2024 $1,750 million of 4.800% senior notes maturing in April 2044 The senior notes are rated A- by Standard & Poor's and Baa1

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top